Plasma concentrations of glucagon, insulin, glucose, and individual plasma amino acids were measured in normal nonobese and obese subjects before and after 3 days of dexamethasone treatment (2 mg/day) and in patients with Cushing's syndrome. The subjects were studied in the basal postabsorptive state and following the infusion of alanine (0.15 g/kg) or ingestion of a protein meal.
A B S T R A C T Plasma concentrations of glucagon, insulin, glucose, and individual plasma amino acids were measured in normal nonobese and obese subjects before and after 3 days of dexamethasone treatment (2 mg/ day) and in patients with Cushing's syndrome. The subjects were studied in the basal postabsorptive state and following the infusion of alanine (0.15 g/kg) or ingestion of a protein meal.
In nonobese subjects dexamethasone treatment resulted in a 55% increment in basal glucagon levels and in a 60-100% increase in the maximal glucagon response to alanine infusion or protein ingestion. In obese subjects, basal glucagon rose by 110% following dexamethasone, while the response to alanine increased fourfold. In patients with Cushing's syndrome basal glucagon levels were 100% higher and the glucagon response to alanine infusion was 170% greater than in normal controls. Dexamethasone treatment in normal subj ects resulted in a 40% rise in plasma alanine concentration which was directly proportional to the rise in basal glucagon. The remaining 14 amino acids were unchanged. In the patients with Cushing's syndrome alanine levels were 40% higher than in normal controls and were directly proportional to basal glucagon concentrations. No other plasma amino acids were significantly altered in the group with Cushing's syndrome.
It is concluded that (a) glucocorticoids increase plasma glucagon concentration in the basal state and in response to protein ingestion or aminogenic stimulation; (b) Received for publication 24 May 1973 and in revised form 29 June 1973. face of obesity and persists in chronic hypercorticism; (c) hyperalaninemia is a characteristic of acute and chronic glucocorticoid excess, and may in turn contribute to steroid-induced hyperglucagonemia; and (d) increased alpha cell secretion may be a contributory factor in the gluconeogenic and diabetogenic effects of INTRODUCTION It is well recognized that glucocorticoids increase the production of glucose by the liver (1). This gluconeogenic effect has generally been ascribed to accelerated protein catabolism (2), resulting in augmented availability of precursor amino acids (3) . Changes in hepatic gluconeogenic processes (4) and resistance to the action of insulin (5) have also been demonstrated following administration of corticosteroids. Despite the evidence indicating enhancement of gluconeogenesis, information concerning the effects of glucocorticoids on the secretion of glucagon has only recently become available (6) . This is of particular interest since a variety of in vitro (7) and in vivo studies (8) indicate that the relative availability of glucagon and insulin determines the net balance of glucose exchange across the liver.
The present study was consequently undertaken to determine the influence of glucocorticoids on alpha cell secretion. This was done by examining the effects of short term (3 days) administration of dexamethasone on plasma glucagon concentration in the basal state and following stimulation with known alpha cell secretogogues: infusion of alanine (9) , and ingestion of protein (8) . The studies were carried out in normal weight subjects as well as in obese individuals. The latter group was investigated because obesity has recently been demonstrated to have a suppressive influence on alpha cell function (9, 10) . The (12) . For the measurement of glucagon, 3 ml of whole blood was added to tubes containing 9 mg EDTA to which 3,000 U of a kallikrein-trypsin inhibitor (Trasylol, FBA Pharmaceuticals, New York) was added in a volume of 0.3 ml. Glucagon was determined in plasma by radioimmunoassay using an antibody (Lot 30 K, supplied by Dr. Roger Unger) which cross reacts minimally with extracts of gastrointestinal tissue (13) . The coefficient of variation with this assay system on replicate analysis of quality control samples over a 6 month period was 8%. All plasma samples from a given patient (pre-and postdexamethasone treatment) were analyzed for glucagon in the same assay. Insulin was measured by radioimmunoassay employing talc to separate bound from free insulin (14) . Total alpha amino nitrogen in serum was determined calorimetrically using ninhydrin (15) . Individual neutral FIGURE 1 Plasma glucagon and glucose concentrations (mean-SE) following the infusion of alanine in six healthy nonobese subjects before (solid lines), and after (broken lines) 3 days of dexamethasone treatment. The solid circles in the upper panel represent those points at which glucagon levels rose to a significantly greater extent after dexamethasone treatment than before (P < 0.05, paired t test). The specific increments in the glucagon response to alanine after dexamethasone were 202±76
pg/ml at 10 min, 152+70 pg/ml at 20 min, 182+70 pg/ml at 30 min, and 137+57 pg/ml at 40 min.
and acidic amino acids were measured by the automated ion exchange chromatographic method (16) on plasma samples deproteinized with sulfosalicyclic acid (17) . Since the plasma samples had been frozen prior to deproteinization, cystine was not measurable (18) . Samples for amino acid analysis were available from eight of the nonobese subjects and from the patients with Cushing's syndrome.
For the statistical analyses, the paired t test (19) was employed in comparing observations pre-and post-dexamethasone treatment in the healthy nonobese and obese groups, each subject thus serving as his own control. In comparing the group with Cushing's syndrome to the healthy nonobese group, the unpaired t test was used (19) .
Data are presented as the mean±tSE.
RESULTS
Basal concentrations of glucagon, glucose, and insulin. In Table I obese subjects before and after dexamethasone administration and for the subjects with Cushing's syndrome. The mean basal levels of glucose and insulin for each of the groups are shown in Table II . Plasma glucagon concentration was higher in 11 of 14 nonobese subjects and in all five obese subjects following dexamethasone treatment (Table I ). The mean increment in plasma glucagon was 55% in the nonobese group and 113% for the obese subjects. M\ean basal glucagon concentration in the patients with Cushing's syndrome was double the value observed in the untreated controls (P < 0.025), and was comparable to the levels demonstrated following dexamethasone administration (Table I) . As anticipated (20) , a small (10-20 mg/100 ml), but significant increase in plasma glucose, and a two-to threefold increment in basal insulin were demonstrable following dexamethasone treatment (Table II) . Basal hyperinsulinemia was also observed in the group with Cushing's syndrome (Table   II) . Response to alanine infusion and protein ingestion. The individual maximal increments in plasma glucagon in response to alanine or protein administration are shown in Table III for each of the subject groups. The absolute glucagon and glucose concentrations following the infusion of alanine are shown in Fig. 1 for the nonobese group, in Fig. 2 for the obese subjects, and in Fig. 3 for the group with Cushing's syndrome. In the nonobese group, dexamethasone resulted in a doubling of the mean maximal increment in plasma glucagon following alanine administration and in a 60% increment in the response to protein ingestion (Table III) . That the augmented glucagon response was not short-lived is indicated by the fact that after dexamethasone administration, a significantly greater increment in plasma glucagon was observed for 40 min during the postinfusion period (Fig. 1) .
In the obese group the effect of dexamethasone treatment on the response to alanine was even more striking. The mean maximal increment in glucagon rose fourfold (Table III) , while mean glucagon levels were significantly higher throughout the two hour period of observation (Fig. 2) . In the group with Cushing's syndrome, the maximal glucagon increment in response to alanine was 170% higher than in untreated controls and was comparable to the dexamethasonetreated subjects (Table III) . Furthermore, the absolute concentration of plasma glucagon after the infusion of alanine remained significantly higher throughout the 2 h period of observation in the group with Cushing's syndrome as compared with untreated controls (Fig. 3) .
In each of the subject groups the augmented glucagon response to alanine or protein associated with dexamethasone administration or chronic hypercorticism was accompanied by a greater increment in plasma glucose (Table II, Figs. 1-3 (Table II) .
Plasma amino acid concentrations. In Table IV , the basal concentrations of 15 individual neutral and acidic amino acids in the nonobese group are shown before and after dexamethasone treatment. A 40% increment was observed in plasma alanine after 3 days of dexamethasone administration (P < 0.01). In marked contrast, no significant changes were observed in the remaining 14 amino acids measured. To evaluate the possible role of endogenous alanine as a glucagon secretogogue, the relation between the changes induced by dexamethasone in plasma alanine and plasma glucagon in the basal state were examined. As shown in Fig. 4 , a significant direct linear correlation was observed (r= 0.75, P < 0.05).
Plasma amino acid concentrations in the patients with Cushing's syndrome are also shown in Table IV . As indicated, plasma alanine concentration in patients with chronic hypercorticism was 40% higher than in healthy subjects studied before dexamethasone treatment (P < 0.01), and was comparable to the value observed in the normal subjects after dexamethasone administration. In contrast, no significant differences were observed between the Cushing group and normal subjects with respect to any of the remaining 14 amino acids measured. Despite the small number of subjects in the group with Cushing's syndrome, a striking relationship was observed between endogenous alanine and glucagon concentrations. As shown in Fig. 5, a I The normal subjects were eight nonobese individuals. § Significance of difference between pre-and post-dexamethasone values (paired t test).
Significance of difference between mean values in patients with
Cushing's syndrome and in untreated (pre-dexamethasone) normal subjects (unpaired t test).
tween basal concentration of plasma alanine and plasma glucagon (r = 0.97, P < 0.01).
In Table V , plasma alanine concentrations following the infusion of this amino acid are shown for the nonobese subjects before and after dexamethasone treatment. No significant differences were noted at any of the times examined. Thus the augmented glucagon response to alanine infusion induced by dexamethasone could not be attributed to higher ambient alanine concentrations during the postinfusion period. Similarly, the mean maximal increment in total alpha amino nitrogen concentration following protein ingestion was not affected by dexamethasone treatment (2.4±0.2 /Lmol/liter, pre-dexamethasone; 2.3+0.2 jumol/liter postdexamethasone.
DISCUSSION
The present data provide evidence that glucocorticoids increase glucagon secretion in man. An elevation in plasma glucagon concentration was demonstrable following short-term (3 day) administration of dexamethasone as well as in association with chronic endogenous or iatrogenic hypercorticism. In a recent study, Marco et al. reported an increased alpha cell response to infusion of arginine in patients treated with prednisolone, but noted only a minimal rise in basal glucagon levels (6) . The current findings indicate that glucocorticoids increase plasma glucagon concentration in the basal state as well as in response to aminogenic stimulation by infusion of alanine. Furthermore, the results also demonstrate augmented alpha cell secretion in response to ingestion of a protein meal (Table III) . The significance of the latter observation is underscored by the recent suggestion that protein ingestion may constitute the most important physiologic stimulus for glucagon secretion (21, 22) . The response to glucocorticoids in obese subjects was of particular interest since truncal, and often generalized obesity is a characteristic finding in chronic hypercorticism (23) . In addition, obesity per se has (10, 24) or infusion of alanine (9, 10) . Furthermore, even in the face of overt diabetes, a blunted alpha cell response has been noted in obese subjects (9, 25) . The present data indicate that obesity does not interfere with the enhancement of glucagon secretion induced by glucocorticoids. In fact, the rise in basal as well as alanine-stimulated glucagon levels following dexamethasone administration was even more marked in obese than in nonobese subjects (Tables I and III) . The observations on the effects of short term administration of dexamethasone and chronic hypercorticism on plasma amino acid levels are of interest both with respect to the mechanism of hyperglucagonemia as well as in regard to the changes in gluconeogenic substrate availability induced by glucocorticoids. Although the protein catabolic effect of corticosteroids has been well documented (2) , and an augmented rise in total alpha amino nitrogen has been demonstrated in eviscerated animals (3), little information is available on the effect of glucocorticoids on individual plasma amino acid concentrations in man. Considering the important role of alanine as the key endogenous gluconeogenic substrate (26, 27) (32) . With respect to the mechanism of glucocorticoidinduced hyperglucagonenmia, alanine has been demonstrated to be a potent stimulus of glucagon secretion (9, 33) . On that basis, hyperalaninemia has been suggested as the possible mediator of augmented glucagon secretion in exercise (34) . In addition, in dogs increased glucagon secretion has been demonstrated to accompany a 30-50% increment in plasma alanine (33) , an elevation comparable to that observed in the present study. Furthermore, in the current investigation a direct linear correlation was observed between the rise in alanine and the increase in plasma glucagon in dexamethasone-treated subjects (Fig. 4) , and between basal alanine and glucagon levels in patients with chronic hypercorticism (Fig. 5) . These data thus raise the possibility that hyperalaninemia may be a contributory factor in glucocorticoid-induced hyperglucagonemia. While this explanation may account for the elevation in basal glucagon levels, it should be noted that the rise in alanine following the infusion of this amino acid was no higher after dexamethasone treatment than before (Table V) . Thus an increase in the responsiveness of the alpha cell to marked elevations in plasma alanine appears to be a contributing factor to the hypersecretory state brought about by dexamethasone. Interference by glucocorticoids with the uptake of glucose by the alpha cell, an effect analogous to the insulin antagonism observed in other tissues (5) , has been suggested as a possible mechanism for the increase in reactivity to aminogenic stimulation (6) .
With regard to the implications of hyperglucagonemia, an increased concentration of glucagon would be expected to enhance hepatic glucose output. Moreover, the interaction of corticosteroids and glucagon is such that adrenal steroids markedly enhance the gluconeogenic response to glucagon (35) . Thus in addition to augmented availability of aminogenic substrate and possible direct effects on hepatic gluconeogenic processes (4), hyperglucagonemiia constitutes an additional miechanismn whereby glucocorticoids augment glucose production and exert a diabetogenic effect. This mechanism appears to be of importance in acute as well as chronic hypercorticism.
Finally, it has been stressed that glucocorticoids are far more effective in increasing gluconeogenesis in the intact organism as compared to their in vitro action when added to the isolated liver (1) . In fact, addition of dexamethasone to perfused liver obtained from adrenalectomized animals fails to increase basal glucose production (35) . This discrepancy between in vivo and in vitro effectiveness in enhancing glucose production has been ascribed to accelerated amino acid mobilization induced by glucocorticoids in the intact organism (1). An additional explanation however, may be provided by the augmentation in glucagon secretion, an effect which would not apply to the isolated liver.
